Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Adc Therapeutics Sa (ADCT)

Adc Therapeutics Sa (ADCT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 533,209
  • Shares Outstanding, K 68,890
  • Annual Sales, $ 33,920 K
  • Annual Income, $ -230,030 K
  • 60-Month Beta 1.95
  • Price/Sales 7.44
  • Price/Cash Flow N/A
  • Price/Book 3.40
Trade ADCT with:

Options Overview Details

View History
  • Implied Volatility 81.66% ( +1.89%)
  • Historical Volatility 79.23%
  • IV Percentile 50%
  • IV Rank 21.02%
  • IV High 170.25% on 06/23/22
  • IV Low 58.08% on 12/21/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 12
  • Volume Avg (30-Day) 14
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 708
  • Open Int (30-Day) 735

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.96
  • Number of Estimates 5
  • High Estimate -0.87
  • Low Estimate -1.03
  • Prior Year -0.95
  • Growth Rate Est. (year over year) -1.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.52 +41.12%
on 06/16/22
8.05 -3.23%
on 06/28/22
+0.40 (+5.41%)
since 05/27/22
3-Month
5.52 +41.12%
on 06/16/22
16.04 -51.43%
on 04/04/22
-6.70 (-46.24%)
since 03/29/22
52-Week
5.52 +41.12%
on 06/16/22
32.00 -75.66%
on 11/02/21
-16.41 (-67.81%)
since 06/29/21

Most Recent Stories

More News
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents

ADC Therapeutics SA (NYSE: ADCT) today announced the first patient has been dosed in LOTIS-7, a Phase 1b clinical trial evaluating ZYNLONTA® in combination with other anti-cancer agents in patients with...

ADCT : 7.79 (+0.65%)
ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer

ADC Therapeutics SA (NYSE: ADCT) announced today it has appointed industry veteran David Gilman to the new role of Chief Business & Strategy Officer reporting to Chief Executive Officer Ameet Mallik effective...

ADCT : 7.79 (+0.65%)
ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma

ADC Therapeutics SA (NYSE: ADCT) announced today results from the ongoing pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in relapsed or refractory (r/r) Hodgkin lymphoma. An overall response...

ADCT : 7.79 (+0.65%)
ADC Therapeutics to Present at the Jefferies Healthcare Conference

ADC Therapeutics SA (NYSE: ADCT) announced today that its Chief Executive Officer, Ameet Mallik, will be participating in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022,...

ADCT : 7.79 (+0.65%)
ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress

ADC Therapeutics SA (NYSE: ADCT), announced today that results from the pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in patients with relapsed or refractory Hodgkin lymphoma have been...

ADCT : 7.79 (+0.65%)
ADC Therapeutics SA (ADCT) Q1 2022 Earnings Call Transcript

ADCT earnings call for the period ending March 31, 2022.

ADCT : 7.79 (+0.65%)
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 52.63% and 55.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ADCT : 7.79 (+0.65%)
CDXC : 1.7500 (-2.23%)
ADC Therapeutics Announces CEO Transition

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients...

ADCT : 7.79 (+0.65%)
ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients...

ADCT : 7.79 (+0.65%)
Should You Buy ADC Therapeutics (ADCT) Ahead of Earnings?

ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ADCT : 7.79 (+0.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.

See More

Key Turning Points

3rd Resistance Point 8.39
2nd Resistance Point 8.16
1st Resistance Point 7.97
Last Price 7.79
1st Support Level 7.55
2nd Support Level 7.32
3rd Support Level 7.13

See More

52-Week High 32.00
Fibonacci 61.8% 21.88
Fibonacci 50% 18.76
Fibonacci 38.2% 15.64
Last Price 7.79
52-Week Low 5.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar